Colon Surgery (Colectomy): A Patient Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

The term "colon cut" is a colloquial expression for surgery on the large bowel (colon). Medically, this encompasses a family of procedures called colectomy (surgical removal of part or all of the colon), performed for a wide range of conditions including colorectal cancer, inflammatory bowel disease, diverticular disease, and bowel obstruction.

The large intestine (colon) runs from the ileocaecal valve to the rectum and is anatomically divided into segments: caecum, ascending (right) colon, hepatic flexure, transverse colon, splenic flexure, descending (left) colon, and sigmoid colon. The operation performed depends on which segment is diseased and the extent of resection required.

Types of colectomy by segment removed:

• Right hemicolectomy: Removes the caecum, ascending colon, hepatic flexure, and a portion of the transverse colon. Used for right-sided colon cancer and Crohn's ileocolitis
• Extended right hemicolectomy: Extends resection to include the transverse colon; used for transverse or hepatic flexure cancers
• Transverse colectomy: Rarely performed in isolation; most transverse colon pathology is addressed by extended right or left hemicolectomy
• Left hemicolectomy: Removes the splenic flexure and descending colon; used for left-sided colon cancer and Crohn's disease
• Sigmoid colectomy: Removes the sigmoid colon; the most common operation for uncomplicated diverticular disease and sigmoid cancer
• Anterior resection: Removes the sigmoid and upper rectum; used for upper rectal and rectosigmoid cancers. A low anterior resection (LAR) joins the colon to the very distal rectum close to the pelvic floor, used for mid-rectal cancers
• Subtotal colectomy: Removes the colon from caecum to sigmoid, preserving the rectum; used for acute colitis, pan-colonic Crohn's, and synchronous multiple cancers
• Total colectomy: Removes the entire colon including the rectum (proctocolectomy); used for familial adenomatous polyposis (FAP) and ulcerative colitis refractory to medical management

Colon surgery is performed laparoscopically (keyhole), robotically, or as open surgery, depending on the indication, urgency, and surgeon expertise. The choice of approach significantly affects recovery time, post-operative pain, and length of hospital stay.

Colectomy is performed for a variety of conditions affecting the colon, ranging from cancer to inflammatory disease to structural complications.

Colorectal Cancer

The most common indication for colectomy. Colorectal cancer (CRC) is the third most common cancer worldwide. Surgical resection with adequate margins and lymphadenectomy (minimum 12 lymph nodes) remains the only potentially curative treatment for non-metastatic CRC. The principle of surgical oncology requires a complete mesocolic excision (CME) — removal of the entire mesocolic envelope containing the lymphovascular pedicle — analogous to total mesorectal excision (TME) for rectal cancer. CME reduces local recurrence rates to <5% in specialist centres. Adjuvant FOLFOX chemotherapy (oxaliplatin + leucovorin + 5-fluorouracil) is standard for stage III (node-positive) and selected stage II high-risk CRC.

Inflammatory Bowel Disease (IBD)

Ulcerative colitis (UC): Medical management (aminosalicylates, corticosteroids, biologic agents — anti-TNF, vedolizumab, ustekinumab, tofacitinib) controls most cases. Surgery (proctocolectomy + ileal pouch-anal anastomosis, "J-pouch" or IPAA) is indicated for refractory disease, steroid-dependent or steroid-resistant disease, high-grade dysplasia, or cancer. The J-pouch creates a functional reservoir from the terminal ileum, enabling patients to pass stool per anum 4–8 times per day without a permanent stoma in most cases.

Crohn's disease: Surgery is not curative (Crohn's can recur anywhere in the GI tract), but is indicated for strictures causing obstruction, fistulae, abscesses, or resection of the most diseased segment to improve quality of life. Conservative (limited) resection is the principle — remove only the diseased segment, preserve as much bowel as possible to prevent short bowel syndrome. Strictureplasty (widening a stricture without resection) is an alternative in patients with extensive small bowel Crohn's.

Diverticular Disease

Diverticula are mucosal pouches that herniate through weaknesses in the sigmoid colon wall. Acute complicated diverticulitis (Hinchey stage III/IV: purulent or faecal peritonitis) requires emergency surgery (sigmoid colectomy with Hartmann's procedure — end colostomy and rectal stump oversewing). Recurrent uncomplicated diverticulitis: the DIRECT trial (2017) and MERIT trial (2019) showed that elective sigmoid colectomy for recurrent uncomplicated diverticulitis reduces diverticulitis recurrence more effectively than conservative management but does not improve quality of life at 6 months. The decision for elective sigmoid colectomy should be individualised, considering frequency and severity of attacks, patient fitness, and quality-of-life impact.

Bowel Obstruction

Acute large bowel obstruction from colorectal cancer or volvulus (sigmoid or caecal) may require emergency colectomy or decompression. A self-expanding metallic stent (SEMS) can be placed endoscopically as a bridge to planned elective (laparoscopic) surgery in selected patients with obstructing left-sided cancer, avoiding an emergency Hartmann's and reducing stoma formation rate.

Familial Adenomatous Polyposis (FAP)

FAP patients develop hundreds to thousands of colorectal adenomas and have a near-100% lifetime risk of colorectal cancer if untreated. Prophylactic proctocolectomy (usually with J-pouch formation) is performed in the late teens/early twenties after confirmed polyposis, before cancers develop.

Colonic Volvulus

Sigmoid volvulus (twisting of the sigmoid colon) causes acute obstruction and ischaemia. First-line decompression is flexible sigmoidoscopy plus rectal tube placement. Recurrence is high (up to 70%), and elective sigmoid colectomy is recommended after the first episode in fit patients to prevent recurrence.

Patient eligibility for colon surgery involves assessing the indication, staging (in cancer cases), overall surgical fitness, and the balance of risk versus benefit. Colon surgery carries meaningful risks, and the decision must be made collaboratively between the surgeon, patient, and often a multidisciplinary team (MDT).

Oncological Assessment (Cancer Patients)

• Staging CT scan of the chest, abdomen, and pelvis is mandatory before elective colorectal cancer resection to exclude metastatic disease and plan the extent of resection
• MRI of the rectum (high-resolution) for rectal tumours to assess mesorectal fascia involvement, nodal status, and extramural vascular invasion (EMVI) — determines whether neoadjuvant chemoradiotherapy is needed before surgery
• Colonoscopy to confirm the diagnosis, obtain biopsies, and exclude synchronous lesions in the rest of the colon
• CEA (carcinoembryonic antigen) baseline level — used post-operatively to monitor for recurrence

Surgical Fitness Assessment

Pre-operative assessment for colon surgery typically includes:

• Cardiopulmonary exercise testing (CPET) in higher-risk patients — VO2max <11 mL/kg/min correlates with increased post-operative morbidity
• ECG, echocardiography if indicated by cardiac history
• Pulmonary function tests in patients with significant COPD
• Full blood count (anaemia from colonic bleeding is very common and should be corrected before elective surgery: iron infusion if iron-deficient, transfusion if Hb <80 g/L in symptomatic patients)
• Renal function, clotting, and group and screen
• Nutritional assessment — significant malnutrition (>10% unintentional weight loss) should be addressed with nutritional support for 2 weeks pre-operatively if time allows

Emergency vs Elective Surgery

Emergency colon surgery (for perforation, complete obstruction, or ischaemia) carries significantly higher morbidity and mortality (10–15% mortality for emergency colectomy vs 1–3% for elective). In emergency cases, stoma formation is more likely because anastomosis is high-risk in an unprepared, contaminated bowel. Patients who are haemodynamically stable with obstructing cancer may be bridged with a colonic stent to allow optimisation before elective laparoscopic resection.

Contraindications

• Metastatic disease where resection is not part of a curative or meaningful palliative plan (discussed in MDT)
• Haemodynamic instability requiring stabilisation before theatre
• Unacceptable anaesthetic risk (ASA grade V) — non-surgical palliation discussed

Colon surgery can be performed by three main approaches: open, laparoscopic (keyhole), or robotic. Large, well-designed randomised controlled trials have established the equivalence of laparoscopic and open surgery for colon cancer outcomes.

Laparoscopic Colectomy

Performed through 3–5 small incisions (5–12 mm ports) with carbon dioxide gas insufflation creating a working space. A camera (laparoscope) provides magnified HD vision. Clinical trials supporting laparoscopic colectomy:

• COST trial (USA, 2004, NEJM): 872 patients with colon cancer randomised to laparoscopic vs open colectomy. No difference in 3-year disease-free survival or overall survival. Laparoscopic group had shorter hospital stay (5 vs 6 days), less pain medication use, and earlier return to activity
• COLOR trial (Europe, 2005, Lancet Oncol): Confirmed oncological equivalence at 3 years; laparoscopic patients had shorter hospital stay and faster recovery
• CLASSIC trial (UK, 2005, Lancet): Found higher conversion rates to open surgery than anticipated (29% for colon, 34% for rectal) but confirmed oncological safety. Catalysed the shift toward high-volume specialist laparoscopic colorectal training in the UK

The laparoscopic approach is now the standard of care for elective colon surgery at specialist centres worldwide. Benefits: shorter hospital stay, less post-operative pain, faster return to normal activities, reduced pulmonary complications, and better short-term quality of life. Oncological outcomes are equivalent to open surgery.

Robotic Colectomy

Uses a robotic surgical system (da Vinci or others) with surgeon control from a console. Advantages over laparoscopic: 3D HD vision, improved instrument articulation in confined spaces. Particularly beneficial for total mesorectal excision (TME) in low rectal cancer where the narrow pelvis limits laparoscopic manoeuvring. The ROLARR trial (2017) compared robotic vs laparoscopic anterior resection for rectal cancer: no significant difference in conversion rate or oncological outcomes, but robotic surgery was significantly more costly. Robotic colectomy is increasingly offered at high-volume centres.

Open Colectomy

A midline laparotomy incision provides full access to the abdominal cavity. Still required for emergency surgery, locally advanced tumours fixed to adjacent structures, prior extensive abdominal surgery with dense adhesions, and technically complex cases not suitable for minimal-access approaches. Recovery time is longer: 7–10 days hospital stay, 6–8 weeks to full activity. Post-operative ileus is more common and prolonged.

Anastomosis: Hand-Sewn vs Stapled

After colon resection, the two ends of bowel are reconnected (anastomosis). Two techniques:

• Stapled anastomosis: Uses a circular stapling device (EEA stapler) or linear stapler (for right-sided anastomosis). Faster, widely reproducible, and associated with lower anastomotic leak rates in most comparative studies. The standard for most elective colorectal anastomoses
• Hand-sewn anastomosis: The surgeon sutures the bowel ends together in two layers (inner absorbable, outer non-absorbable or absorbable). Required when anatomy or bowel diameter excludes a stapler (e.g. very narrow mesentery, unusual angulation). Excellent results in experienced hands

Stoma Formation

A stoma (diversion of bowel to the abdominal wall skin) may be fashioned at the time of colectomy:

• End colostomy (Hartmann's procedure): Used in emergency surgery for perforated or obstructed left-sided disease when anastomosis is unsafe. The proximal colon is brought to the skin; the rectal stump is oversewn. Reversal (Hartmann's reversal) is possible in fit patients 3–6 months later
• Defunctioning loop ileostomy: A loop of terminal ileum brought to the skin as a temporary stoma to protect a newly formed colorectal anastomosis (particularly low anterior resection anastomosis) from the consequences of a leak. Anastomotic leak rates after low anterior resection range from 2–7%; a defunctioning loop ileostomy reduces the clinical severity of leaks. Reversed at 8–12 weeks post-operatively when the anastomosis has healed, confirmed by gastrografin enema

For most indications, colectomy offers significant clinical benefit that outweighs the surgical risks, whether the aim is cure, cancer control, symptom relief, or prevention of life-threatening complications.

Curative Intent in Colorectal Cancer

Surgical resection with complete mesocolic excision (CME) and adequate lymphadenectomy is the only potentially curative treatment for non-metastatic colorectal cancer. Five-year overall survival rates by stage: stage I >90%, stage II 70–85%, stage III 40–75% (with adjuvant FOLFOX chemotherapy), stage IV (metastatic, resectable liver-only disease) 25–40% with hepatic metastasectomy. Without surgery, locally resectable CRC is invariably fatal. Even in metastatic disease, palliative resection of the primary tumour can prevent obstruction and bleeding.

Symptom Relief

Recurrent diverticulitis, painful stricturing Crohn's disease, obstructing sigmoid volvulus, and bleeding from colonic angiodysplasia all produce significant impairment of quality of life. Surgical resection provides definitive symptom control and can dramatically improve wellbeing when medical management has failed.

Prevention of Cancer in IBD and FAP

Prophylactic proctocolectomy in FAP and timely colectomy in refractory UC with dysplasia prevents the development of colorectal cancer in high-risk individuals. FAP patients not operated on have a near-100% cancer risk by age 50; prophylactic surgery eliminates this risk.

ERAS Protocol Benefits

Enhanced Recovery After Surgery (ERAS) protocols, developed primarily for colorectal surgery (Gustafsson et al., ERAS Society guidelines, updated 2019), have transformed surgical recovery by combining multiple evidence-based perioperative interventions:

• Pre-operative carbohydrate loading: Oral carbohydrate drink (800 mL the night before, 400 mL 2 hours before surgery) reduces insulin resistance and nitrogen catabolism, improving energy reserves
• No routine nasogastric tube: Avoidance of routine nasogastric decompression reduces discomfort and allows earlier oral intake
• Goal-directed fluid therapy: Avoidance of both fluid overload (which delays gut recovery) and hypovolaemia; oesophageal Doppler monitoring guides intra-operative fluid administration
• Early oral intake: Oral fluids within 4–6 hours of surgery, full diet within 24 hours. Early feeding reduces anastomotic complication rates and hospital stay
• Early mobilisation: Out of bed within 6 hours of surgery; structured physiotherapy programme reduces pulmonary complications and DVT risk
• Multimodal analgesia: Paracetamol + NSAID + wound infiltration with local anaesthetic + transversus abdominis plane (TAP) block reduces opioid requirements and opioid-related ileus
• Thromboprophylaxis: Low-molecular-weight heparin (e.g. enoxaparin 40 mg once daily) for 28 days post-operatively in cancer patients, combined with graduated compression stockings

ERAS protocols reduce hospital stay for laparoscopic colectomy from 7–8 days (traditional care) to 3–4 days, cut surgical complication rates by 30–40%, and enable most patients to return to normal activities within 2–4 weeks.

Colon surgery carries significant risks that every patient must be fully informed about before surgery. Complication rates depend on the urgency of surgery (elective vs emergency), the patient's pre-existing health, the surgical approach, and the experience of the surgical team.

Anastomotic Leak

The most feared complication of colon surgery. Anastomotic leak occurs when the join between the two bowel ends fails to heal, leaking bowel contents into the peritoneal cavity. Overall leak rates for colonic anastomosis are 2–4%; for low anterior resection (rectosigmoid anastomosis close to the pelvic floor), the rate is higher at 5–10%. Anastomotic leak typically presents on post-operative days 3–7 with fever, tachycardia, peritonism, and rising CRP. CT with rectal contrast confirms the diagnosis. Management: drain insertion (radiologically guided if a small contained leak), and in cases of free perforation or sepsis, return to theatre for washout and stoma formation. A defunctioning loop ileostomy does not prevent anastomotic leak but reduces its clinical severity. Anastomotic leak significantly increases mortality risk in the early post-operative period.

Surgical Site Infection (SSI)

Wound infection (superficial SSI) occurs in 5–15% of open colectomy incisions but is much less common with laparoscopic keyhole incisions (2–5%). Deep surgical site infection (intra-abdominal abscess) occurs in 2–5% of cases. Prophylactic antibiotics (typically IV co-amoxiclav or a cephalosporin plus metronidazole) given 30–60 minutes before skin incision reduce SSI rates by 40–60%. Bowel preparation (polyethylene glycol or sodium phosphate plus oral antibiotics: neomycin + metronidazole) before elective left-sided resection further reduces infectious complications.

Post-Operative Ileus (POI)

Temporary impairment of bowel motility after surgery, causing abdominal distension, nausea, vomiting, and inability to tolerate oral intake. POI is more common and prolonged after open vs laparoscopic surgery and is exacerbated by excessive opioid use. Most POI resolves within 3–5 days. Prolonged ileus (>5 days, "paralytic ileus" or "post-operative ileus") requires nasogastric decompression, IV fluid, and exclusion of mechanical obstruction. ERAS protocols (early mobilisation, opioid-sparing analgesia, early feeding) substantially reduce POI incidence.

Bleeding

Intra-operative haemorrhage from mesenteric vessels, retroperitoneal structures, or major vessels (IMA, IMV) occurs in <1% of laparoscopic and <2% of open procedures. Post-operative haemorrhage from bleeding anastomosis or pedicle ligation presents with rectal bleeding or abdominal haematoma. Minor anastomotic bleeding often settles with conservative management; significant bleeding may require colonoscopic haemostasis or re-operation.

Stoma-Related Complications

When a stoma (ileostomy or colostomy) is formed, patients must adjust to a major change in bodily function. Stoma complications include skin excoriation (from effluent contact), parastomal hernia (herniation of bowel around the stoma site, 10–40% of permanent stomas), stoma retraction, and prolapse. Stoma nurses (specialist nurses in stomal therapy, "ET nurses") are essential for education, fitting, and management of stoma complications.

Sexual and Urological Dysfunction

Pelvic nerve damage during surgery for sigmoid colon and rectal disease can cause erectile dysfunction (in men) and retrograde ejaculation (from damage to the hypogastric plexus). Female patients may experience dyspareunia from altered pelvic anatomy. Total mesorectal excision for rectal cancer carries a 10–30% risk of sexual dysfunction even in experienced hands. Bladder dysfunction (urinary retention, stress incontinence) results from autonomic pelvic nerve injury in 5–10% of rectal surgery cases.

Deep Vein Thrombosis and Pulmonary Embolism

Colorectal cancer surgery carries the highest DVT risk of any elective operation (Caprini score typically 5+, "very high risk"). Extended (28-day) post-discharge LMWH prophylaxis is recommended by NICE and ERAS guidelines for all colorectal cancer resections. Graduated compression stockings are used perioperatively. Without prophylaxis, symptomatic DVT/PE rates after colorectal cancer surgery reach 5–10%.

Recovery from colon surgery is structured around three phases: hospital recovery, early post-discharge, and long-term surveillance (for cancer patients).

In-Hospital Recovery

Under ERAS protocols, patients typically leave hospital within 3–5 days after laparoscopic colectomy and 5–7 days after open colectomy, once they can eat and drink freely, have had their first bowel movement or passing of flatus (confirming bowel continuity), pain is controlled with oral analgesia, and there are no signs of early complications. Daily clinical review includes temperature chart, abdominal examination, wound check, and review of drain output where drains are used.

Post-Discharge Recovery (First 6 Weeks)

• Diet: Most patients can eat a normal diet from day 1 post-surgery. A low-fibre diet is not necessary after right-sided or sigmoid resection. After anterior resection, some patients develop "anterior resection syndrome" (altered bowel habit with frequency and urgency); dietary advice from a specialist dietitian helps
• Activity: Light walking from day 1; avoid heavy lifting (>3–5 kg) for 4–6 weeks. Most patients return to desk work at 2–4 weeks and manual work at 6–8 weeks
• Wound care: Absorbable sutures need no removal; staples are removed at 7–10 days. Laparoscopic port sites heal quickly. Midline laparotomy wounds take 6–8 weeks to achieve full tensile strength
• Driving: Not until comfortable performing an emergency stop, typically 2–4 weeks post-laparoscopic surgery and 4–6 weeks post-open surgery
• Stoma reversal: Loop ileostomy reversal (if formed) is typically planned at 8–12 weeks post-operatively, after a gastrografin enema confirms a healed anastomosis

Oncology Follow-Up (Cancer Patients)

Post-operative oncology surveillance for colorectal cancer follows national guideline protocols (ESMO, NCCN). Typically:

• CT chest/abdomen/pelvis at 12 and 36 months post-surgery (or more frequently in stage III)
• Colonoscopy at 1 year post-surgery (to exclude synchronous lesions missed pre-operatively), then every 5 years if clear
• CEA every 3–6 months for 2 years, then 6-monthly for years 3–5. Rising CEA triggers investigation for recurrence (CT, PET-CT)
• Adjuvant FOLFOX chemotherapy (oxaliplatin + 5-FU + leucovorin) for 6 months in stage III patients; discussed in MDT for high-risk stage II

Stoma Management and Reversal

Patients with a temporary stoma have ongoing stoma nurse support. Key reversal criteria for Hartmann's reversal: patient is fully recovered from initial surgery (minimum 3 months), nutritionally replete, and anaesthetically fit. The Hartmann's reversal operation is technically demanding; morbidity rates of 15–30% have been reported. Surgeons experienced in laparoscopic reversal achieve lower complication rates and shorter hospital stay than open reversal.

The cost of colon surgery varies substantially by surgical approach (laparoscopic vs open vs robotic), the health system, and whether the surgery is elective or emergency.

Surgical Approach Costs

• Open colectomy: USD 15,000–35,000 total hospital cost in the USA, including surgeon fee, anaesthesia, operating theatre, ICU if needed, and 7–10-day hospital stay. Longer length of stay is the primary driver of cost
• Laparoscopic colectomy: Higher consumable and equipment costs (laparoscopic ports, energy devices, staplers: USD 1,500–3,500 extra in consumables) but shorter hospital stay (3–5 days) means total costs are comparable to or less than open surgery. Total USA hospital cost: USD 18,000–40,000
• Robotic colectomy: Robot lease and consumable costs add USD 3,000–6,000 per case vs laparoscopic. USA total cost: USD 25,000–50,000. Not yet cost-effective compared to laparoscopic for standard colectomy based on current evidence, though the gap narrows for complex pelvic surgery

Medical Tourism Costs

• India: Laparoscopic right or sigmoid colectomy at a top private hospital (Apollo, Fortis, Medanta): INR 250,000–600,000 (USD 3,000–7,500). This includes surgeon, anaesthesia, hospital stay, and post-operative care. Oncological outcomes from experienced Indian colorectal surgeons trained in the UK, USA, or Germany are comparable to Western centres
• Thailand: Laparoscopic colectomy at Bumrungrad or Bangkok Hospital: USD 5,000–12,000, with JCI accreditation and internationally trained surgeons
• Turkey: USD 4,000–10,000 for laparoscopic colectomy at accredited private hospitals; robotic surgery also available at selected centres
• Mexico: USD 4,000–9,000 for laparoscopic colectomy, particularly popular for USA-based patients due to proximity

Additional Cost Considerations

• Stoma supplies: Ongoing cost of stoma bags, flanges, accessories. USD 200–500/month in the USA; covered by NHS in the UK; available at lower cost in India and Asia
• Adjuvant chemotherapy: FOLFOX for 6 months adds USD 20,000–50,000 (drug costs alone) in the USA. Available at much lower cost in India (capecitabine-based CAPOX: USD 500–2,000 for the full course) and in developing countries with access to generic oxaliplatin
• Pre-operative investigations: CT staging, colonoscopy, MRI (for rectal tumours), CPET, and laboratory work add USD 2,000–5,000 before surgery

For selected indications, alternatives to open or laparoscopic colectomy exist. The appropriateness of each alternative depends on the specific diagnosis, disease stage, and patient characteristics.

Endoscopic Resection (EMR and ESD)

Large adenomatous polyps and early (T1) colorectal cancers confined to the submucosa can be removed endoscopically without surgery. Endoscopic mucosal resection (EMR) uses a submucosal saline injection to lift the lesion and a snare to remove it piecemeal or en bloc. Endoscopic submucosal dissection (ESD), more commonly performed in Japan and Korea, allows en bloc resection of larger lesions with precise lateral margins. ESD for T1 colon cancer with favourable histology (low-grade, no lymphovascular invasion, clear margins) can be curative without surgery. Decision for endoscopic vs surgical resection of early CRC is made in MDT.

Transanal Minimally Invasive Surgery (TAMIS) / TEMS

For rectal tumours not reachable by standard colonoscopy, transanal endoscopic microsurgery (TEMS) or TAMIS platforms allow full-thickness excision of early rectal lesions via the anus without abdominal incision. Suitable for T1 rectal cancer (selected cases), large rectal adenomas, and carcinoid tumours. Requires experienced colorectal surgeons with dedicated equipment.

Conservative Management with Surveillance (Diverticular Disease)

Most episodes of uncomplicated diverticulitis are managed with antibiotics and dietary modification. The AVOD trial (2012) and DIABOLO trial (2017) questioned whether antibiotics are even necessary for uncomplicated diverticulitis. For patients with recurrent uncomplicated diverticulitis, conservative management (dietary fibre, mesalazine in some studies) versus sigmoid colectomy is a shared decision based on quality-of-life impact (DIRECT and MERIT trials showed surgery superior for recurrence but not quality of life at 6 months).

Biologics and Immunosuppression for IBD

Advances in IBD therapy have reduced the need for surgery. Anti-TNF agents (infliximab, adalimumab), vedolizumab (gut-selective anti-integrin), ustekinumab (anti-IL-12/23), and JAK inhibitors (tofacitinib, upadacitinib) achieve mucosal healing in a substantial proportion of UC and Crohn's patients who previously would have required surgery. However, IBD patients with medically refractory disease, steroid dependence, or dysplasia still require surgical management.

Colonic Stenting (Bridge to Surgery)

For obstructing left-sided colorectal cancer, self-expanding metallic stents (SEMS) placed endoscopically decompress the obstructed bowel as a bridge to elective laparoscopic surgery, avoiding an emergency Hartmann's and its associated morbidity and permanent stoma rate. The ESCO trial and STENT trial established the safety and efficacy of this approach in selected patients. Note: stenting is not appropriate for right-sided obstruction or if perforation risk is high.

Palliative Chemotherapy (Metastatic CRC)

For unresectable metastatic colorectal cancer, the primary tumour may be managed non-surgically if it is not causing obstruction, bleeding, or perforation. Modern first-line systemic regimens (FOLFOX or FOLFIRI ± bevacizumab, cetuximab [RAS wild-type], or pembrolizumab [MSI-H]) achieve median overall survival of 30+ months in selected patients. Resection of the primary in asymptomatic patients with synchronous unresectable metastases does not improve survival (SYNCHRONOUS trial) and should not be performed routinely.